Hermetica Superfood Encyclopedia
The Short Answer
Lanceleaf Waltheria contains alkaloids (waltheriones A and C), flavonoids (quercetin, chrysosplenol E, epicatechin), and triterpenoids that exert antibacterial and anti-inflammatory activity through NF-κB signaling inhibition and modulation of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and IL-8. Preclinical evidence extrapolated from the closely related species Waltheria indica demonstrates dose-dependent bronchorelaxation in rat tracheal ring models (hydroalcoholic extract, 10–3000 µg/mL) and suppression of NF-κB-driven inflammation in human macrophage cell lines, though no human clinical trials have been completed.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordWaltheria lanceolata benefits
Lanceleaf Waltheria — botanical close-up
Health Benefits
**Antibacterial Activity**
Traditional Ivorian use targets bacterial infections, and phytochemicals including waltherione alkaloids and tannins in related Waltheria species demonstrate inhibitory effects against pathogenic bacteria in vitro, likely through membrane disruption and enzyme inhibition.
**Anti-Inflammatory Effects**
Extracts of the Waltheria genus inhibit NF-κB signaling in LPS/TNF-α/IFN-γ-stimulated human macrophages, reducing mRNA and protein expression of TNF-α, IL-1β, IL-6, and IL-8, which underpins relief of inflammatory conditions.
**Bronchorelaxant Properties**
Hydroalcoholic extracts of closely related Waltheria indica relax contracted airway smooth muscle in rat tracheal ring models via ATP-sensitive potassium channel activation (partially blocked by glibenclamide) and potential Ca²⁺ channel inhibition, suggesting utility in respiratory conditions such as asthma.
**Cancer Chemopreventive Potential**: Waltherione A, waltherione C, and chrysosplenol E inhibit NF-κB transcriptional activity and induce quinone reductase (QR)
a phase II detoxification enzyme — in HEK293 and Hepa1c1c7 cell models at low-to-mid micromolar concentrations, indicating chemopreventive signaling modulation.
**Antioxidant Defense**
Flavonoids quercetin and epicatechin present in Waltheria extracts scavenge reactive oxygen species and inhibit 5-lipoxygenase (5-LOX), reducing oxidative stress and leukotriene-mediated inflammation simultaneously.
**Smooth Muscle Relaxation**
Quercetin and epicatechin contribute to vascular and airway smooth muscle relaxation by modulating calcium flux and potassium channel conductance, offering potential cardiovascular and respiratory benefits beyond direct antibacterial effects.
**Immune Modulation**
In vitro evidence from human macrophage studies shows Waltheria extracts down-regulate both pro-inflammatory (TNF-α, IL-1β) and regulatory cytokines (IL-1ra), suggesting a balanced immunomodulatory profile rather than simple immunosuppression.
Origin & History
Natural habitat
Waltheria lanceolata is a flowering shrub native to sub-Saharan Africa, including Côte d'Ivoire (Ivory Coast), where it grows in tropical savanna and forest margins at low to mid elevations. The plant thrives in well-drained lateritic soils under high humidity and full sun exposure, common to West African ecological zones. It is not commercially cultivated and is harvested wild by traditional practitioners who use the leafy stems and aerial parts in medicinal preparations.
“Waltheria lanceolata holds a recognized place in Ivorian (Côte d'Ivoire) traditional medicine, where healers prepare decoctions of the leafy stems to treat bacterial infections, wounds, and inflammatory conditions in community health practice. Across West and Central Africa, plants of the Waltheria genus are broadly valued as multi-purpose medicinal shrubs, with uses spanning treatment of fever, skin infections, respiratory complaints, and gastrointestinal disorders. In Hawaiian traditional medicine, the closely related Waltheria indica (known as 'uhaloa) has been used for centuries as a throat soother, with bark and root decoctions administered for sore throats and respiratory conditions, indicating a pan-tropical ethnopharmacological convergence. The genus name Waltheria honors the 18th-century German botanist Augustin Friedrich Walther, and the species' traditional uses have attracted modern pharmacognostic interest as part of broader African medicinal plant documentation efforts.”Traditional Medicine
Scientific Research
There are no published clinical trials in humans for Waltheria lanceolata specifically, and the scientific evidence base relies entirely on preclinical studies of the closely related species Waltheria indica, from which mechanistic inference is drawn. In vitro studies in human macrophage cell lines (LPS/TNF-α/IFN-γ stimulation models) documented significant reductions in NF-κB-driven cytokine expression, and a cell-based screen across HEK293 and Hepa1c1c7 lines tested 29 isolated compounds, identifying 11 active agents at low-to-mid micromolar concentrations for NF-κB inhibition or QR induction. Rat tracheal ring models demonstrated dose-dependent bronchorelaxation across a hydroalcoholic extract concentration range of 10–3000 µg/mL, though sample sizes and full statistical parameters were not reported in available literature. Acute oral toxicity studies in mice showed no observed adverse effects, providing a preliminary safety signal, but the overall evidence quality is low (preclinical only), with no randomized controlled trials, pharmacokinetic data, or bioavailability studies published for either Waltheria lanceolata or indica.
Preparation & Dosage
Traditional preparation
**Traditional Aqueous Decoction**
Leafy stems or aerial parts simmered in water; this is the primary preparation in Ivorian traditional medicine for antibacterial and anti-inflammatory applications; no standardized volume or concentration has been established scientifically.
**Hydroalcoholic Extract (Experimental)**
Used in preclinical bronchorelaxant studies at concentrations of 10–3000 µg/mL in vitro; no equivalent human oral dose has been derived or validated.
**Powdered Aerial Parts**
Dried and ground plant material used in some African traditional contexts; no commercial standardization exists.
**Standardization**
No standardized extract (e.g., defined % waltheriones or quercetin) is currently available commercially; phytochemical content varies by harvest season, geography, and preparation method.
**Effective Human Dose**
Not established; no clinical dose-finding trials have been published for Waltheria lanceolata or indica.
**Timing**
No evidence-based guidance on dosing frequency or timing relative to meals; traditional use is typically as a daily decoction during acute illness.
Nutritional Profile
Waltheria lanceolata has not been subjected to formal nutritional composition analysis, and no macronutrient, micronutrient, or caloric data are documented in the scientific literature. Phytochemical profiling of the closely related Waltheria indica identifies qualitatively positive screening results for flavonoids (quercetin, epicatechin, chrysosplenol E), alkaloids (waltherione A and C — β-carboline class), saponins, tannins, steroids, triterpenoids, and coumarins in leafy stem and aerial part extracts, though precise quantitative concentrations (mg/g dry weight) have not been published. Waltherione A and waltherione C are considered the most pharmacologically distinctive compounds and are present in detectable concentrations in traditional decoctions of aerial parts. Bioavailability of these compounds in humans is unknown, as no pharmacokinetic studies measuring absorption, distribution, metabolism, or excretion of Waltheria phytochemicals have been conducted in human subjects.
How It Works
Mechanism of Action
Waltherione A and waltherione C — β-carboline alkaloids characteristic of the Waltheria genus — inhibit NF-κB transcriptional activation, suppressing downstream expression of TNF-α, TNFRII, IL-1β, IL-6, and IL-8 at the mRNA and protein level in stimulated macrophages, thereby attenuating the inflammatory cascade. Chrysosplenol E (a methylated flavonoid) exhibits dual activity by both inhibiting NF-κB and inducing quinone reductase (QR) in cancer cell models, engaging Nrf2-ARE pathway elements that upregulate phase II detoxification enzymes. The bronchorelaxant mechanism involves activation of ATP-sensitive K⁺ channels in airway smooth muscle, hyperpolarizing the cell membrane and reducing contractile tone, with additional contributions from probable Ca²⁺ channel blockade or muscarinic receptor antagonism as demonstrated by differential antagonist profiling in rat tracheal ring assays. Quercetin and epicatechin further contribute to the anti-inflammatory phenotype through 5-lipoxygenase inhibition, reducing leukotriene B4 synthesis and limiting neutrophil recruitment to infection and inflammation sites.
Clinical Evidence
No human clinical trials have been conducted on Waltheria lanceolata or its close relative Waltheria indica as of current available literature, meaning all clinical inferences are extrapolated from in vitro and animal preclinical models. The in vitro macrophage studies measuring NF-κB, TNF-α, IL-1β, IL-6, and IL-8 expression provide mechanistic plausibility for anti-inflammatory and potentially antibacterial effects but do not constitute clinical efficacy evidence. Rat tracheal smooth muscle relaxation studies support the ethnopharmacological use for respiratory complaints but lack the translational validation of human pharmacokinetic data, bioavailability confirmation, or dose-response curves applicable to human supplementation. Confidence in clinical outcomes is therefore very low; the herb's use remains grounded in traditional Ivorian ethnomedicine, and rigorous clinical investigation is needed before any evidence-based therapeutic claims can be substantiated.
Safety & Interactions
Acute oral toxicity studies of Waltheria indica extracts in mice showed no observed adverse effects, providing a preliminary indication of short-term safety at tested doses, but this data cannot be directly extrapolated to Waltheria lanceolata or to chronic human use. No human adverse event reports, systematic safety evaluations, or maximum tolerated dose data exist for either species, leaving the long-term safety profile entirely undetermined. The in vitro finding that bronchorelaxant activity is partially blocked by glibenclamide (an ATP-sensitive K⁺ channel inhibitor and antidiabetic drug) raises a theoretical concern for pharmacodynamic interaction with sulfonylurea antidiabetic medications, though no clinical drug interaction studies have been performed. Due to the complete absence of safety data in pregnant or lactating women, children, or individuals with chronic illness, use of Waltheria lanceolata preparations in these populations is not advisable until further research is conducted.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Waltheria lanceolataLanceleaf WaltheriaAfrican WaltheriaWaltheria (Ivorian variety)
Frequently Asked Questions
What is Waltheria lanceolata used for in traditional African medicine?
In Ivorian (Côte d'Ivoire) traditional medicine, Waltheria lanceolata is primarily used as an antibacterial remedy for infections and as an anti-inflammatory agent. Healers prepare aqueous decoctions of the leafy stems and aerial parts, which are administered during acute illness episodes involving bacterial infections, wounds, or inflammatory conditions.
What are the active compounds in Waltheria lanceolata?
Based on phytochemical profiling of the closely related species Waltheria indica, the primary bioactive compounds in the Waltheria genus include the β-carboline alkaloids waltherione A and waltherione C, the flavonoids quercetin, epicatechin, and chrysosplenol E, as well as saponins, tannins, triterpenoids, and coumarins. Waltheriones A and C are considered the most pharmacologically distinctive alkaloids and are the focus of mechanistic research into NF-κB inhibition and cancer chemopreventive activity.
Is there clinical trial evidence supporting Waltheria lanceolata health benefits?
No human clinical trials have been published for Waltheria lanceolata or the closely related Waltheria indica as of current available literature. All evidence is derived from in vitro cell-based studies and animal models, including human macrophage assays showing NF-κB suppression and rat tracheal ring experiments demonstrating bronchorelaxation at extract concentrations of 10–3000 µg/mL; this evidence is considered preliminary and does not establish clinical efficacy.
How does Waltheria lanceolata fight inflammation at the molecular level?
The waltherione alkaloids in Waltheria extracts inhibit NF-κB transcriptional activation, thereby reducing expression of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and IL-8 at both mRNA and protein levels in stimulated immune cells. Simultaneously, quercetin and epicatechin inhibit 5-lipoxygenase (5-LOX), blocking leukotriene B4 synthesis and neutrophil recruitment, while chrysosplenol E adds dual activity by also inducing the detoxifying enzyme quinone reductase via Nrf2-ARE pathway engagement.
Is Waltheria lanceolata safe to take as a supplement?
Formal safety data for Waltheria lanceolata in humans does not exist; the only available toxicity data comes from acute oral studies of Waltheria indica extracts in mice, which showed no adverse effects at tested doses. A theoretical drug interaction concern exists with sulfonylurea antidiabetic medications (such as glibenclamide) based on in vitro potassium channel data, and the complete absence of safety data in pregnant women, nursing mothers, or individuals with chronic diseases means these populations should avoid use until rigorous safety studies are conducted.
Does Waltheria lanceolata interact with common antibiotics or antimicrobial medications?
While Waltheria lanceolata contains compounds with antibacterial properties, there is limited clinical data on direct interactions with prescription antibiotics. Due to the presence of alkaloids and tannins that affect bacterial cell membranes, theoretical interactions with aminoglycosides or fluoroquinolones are possible but not well-documented in humans. Consult a healthcare provider before combining Waltheria lanceolata with antibiotic therapy to avoid potential synergistic or antagonistic effects.
What is the most effective form of Waltheria lanceolata supplement—extract, dried herb, or standardized concentrate?
Standardized extracts containing quantified levels of waltherione alkaloids and tannins are likely more bioavailable and consistent than whole dried herb, though comparative human studies are lacking. Liquid extracts and capsules of concentrated plant material may provide better absorption than raw dried preparations, especially for targeting inflammatory pathways. The optimal form depends on individual absorption capacity and the specific health goal, making professional guidance advisable for consistent results.
Who should avoid Waltheria lanceolata supplementation due to its alkaloid and tannin content?
Individuals with tannin sensitivity, those taking iron supplements, and people with certain gastrointestinal conditions like irritable bowel syndrome should exercise caution, as high tannin levels can reduce nutrient absorption and cause digestive upset. Pregnant and nursing women should avoid supplementation due to insufficient safety data on alkaloid exposure during these sensitive periods. People with liver or kidney impairment should consult a healthcare provider before use, as alkaloid metabolism may be compromised.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w lanceleaf-waltheria-waltheria-lanceolata curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
